ALNY

#340
Alnylam Pharmaceuticals, Inc. - Common Stock
301.9 7 USD
-0.73%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
297.62
302.68
Range Annuel
284.28
495.55
Changement quotidien
-0.73%
Changement Mensuel
-1.79%
Evolution sur 6 mois
-32.88%
Changement Annuel
+5.14%
Clôture Précédente
304.2 0
Open
297.7 2
Low
297.6 2
High
302.6 8
Volume
1 979
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 40.32 B
  • Employee 2 500
  • Founded 2002
  • CEO Yvonne Greenstreet
  • Website www.alnylam.com
  • Headquarter Massachusetts, United States
  • FIGI BBG000BFGNJ5
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
170.67
ratio cours/chiffre d'affaires
14.42

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Nouvelles